Format

Send to

Choose Destination
See comment in PubMed Commons below

Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go.

Author information

  • 1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University, Montreal, Quebec, Canada. allan.sniderman@muhc.mcgill.ca

Abstract

PURPOSE OF REVIEW:

Getting low-density lipoprotein to the right level in patients with type 2 diabetes should be relatively easy, given the potent pharmacological therapy that is available and the fact that low-density lipoprotein C is typically normal in these patients. Getting it right means getting the target for therapy right, however. The article examines the criteria that should be used to make this choice.

RECENT FINDINGS:

In comparing different parameters, three criteria, in particular, need to be taken into account: the on-treatment predictive value of any parameter; the value relative to the population of one parameter compared with another, namely which is more deviant from the norm; and the concurrent level of high-density lipoprotein. The evidence from the low-density lipoprotein-lowering trials indicates that low-density lipoprotein C is not nearly as good as non-high-density lipoprotein C as a guide for the adequacy of low-density lipoprotein lowering, or, better still, apoB, with the apoB/apoA-I ratio being clearly the best of all.

SUMMARY:

The evidence from the major clinical trials indicates the best single index of the adequacy of low-density lipoprotein lowering is the apoB/apoA-I ratio. Clinical practice should adapt to clinical evidence and, therefore, guidelines should be based on apolipoproteins rather than the conventional cholesterol indices.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk